Neupath Health Launches Arthrosamid® for Knee Osteoarthritis in North America
NeuPath Health Inc. (TSXV:NPTH), a leading provider of chronic pain treatment through its network of clinics, has announced the first-ever injection of Arthrosamid in North America at its Mississauga, Ontario clinic. Previously, patients seeking this innovative hydrogel, which has demonstrated up to four years of pain relief for knee osteoarthritis, would have had to travel to Europe to access it. The injection was made possible following the approval of Arthrosamid by Health Canada, marking a significant milestone in providing advanced treatment for knee osteoarthritis sufferers in North America.
NeuPath Health Inc. (TSXV:NPTH), a prominent healthcare provider specializing in chronic pain management, has reached a significant milestone by administering the first-ever Arthrosamid injection in North America at its Mississauga, Ontario clinic. This new treatment option has been shown to provide knee osteoarthritis (OA) patients with long-lasting relief, offering up to four years of pain relief through a single injection. Previously, patients seeking this innovative hydrogel treatment had to travel to Europe, making its approval by Health Canada a breakthrough for Canadian patients.
“This is a major step forward in osteoarthritis options for Canadians,” said Joe Walewicz, NeuPath’s Chief Executive Officer. “It underscores our commitment to provide the best chronic pain care to our patients as we expand our clinic network and services across Canada. We continue to seek out proven, innovative treatments that leverage our growing market presence and the skills of our healthcare professionals.”
Osteoarthritis, particularly knee osteoarthritis, affects over four million Canadians, and is a leading cause of chronic pain, mobility limitations, and decreased quality of life. The economic toll of arthritis in Canada is substantial, with an estimated cost of $6.4 billion annually, accounting for nearly a third of the total expense associated with musculoskeletal diseases. Globally, osteoarthritis remains a leading cause of disability among older adults, and conventional treatments like painkillers and corticosteroid injections provide only temporary relief. By offering Arthrosamid, NeuPath expands its role as a leader in the treatment of chronic pain and further solidifies its position in the healthcare market as the company continues to broaden its reach across Canada.
About Arthrosamid
Arthrosamid (2.5% iPAAG) is a groundbreaking, non-biodegradable hydrogel injection created by Contura International A/S, a biotechnology company based in Denmark. Unlike traditional osteoarthritis injections, which provide temporary relief, Arthrosamid integrates directly into the synovial tissue of the knee, offering longer-lasting pain relief with just a single injection. The hydrogel works by cushioning the joint, alleviating pain, and reducing inflammation, providing patients with extended relief. As a result, Arthrosamid represents a major advancement in non-surgical solutions for osteoarthritis, helping to improve the overall quality of life for those suffering from this debilitating condition. Hydrogel-based injections have already been administered to over 1.4 million patients worldwide, further validating the safety and effectiveness of this innovative treatment.
NeuPath’s Commitment to Patient Care and Expansion
NeuPath’s integration of Arthrosamid into its range of services aligns with its ongoing mission to improve the lives of individuals living with chronic pain. The company operates a comprehensive network of healthcare clinics across Ontario and Alberta, where it provides specialized care for patients with chronic pain, musculoskeletal injuries, sports-related injuries, and concussions. NeuPath’s multidisciplinary approach combines expert medical professionals with cutting-edge treatments and rehabilitation services, ensuring that every patient receives personalized and effective care tailored to their specific needs.
NeuPath also offers workplace health services, independent medical assessments for employers, and contract research services to pharmaceutical and biotechnology companies. This diverse range of services helps NeuPath extend its reach into various sectors, further cementing its status as a key player in the Canadian healthcare landscape. As NeuPath continues to grow, the company is committed to delivering improved access to care and better outcomes for patients across the country.
By introducing Arthrosamid to its portfolio of services, NeuPath is enhancing its ability to offer innovative, effective solutions to those suffering from knee osteoarthritis, a condition that traditionally lacked long-term, non-invasive treatment options. With the approval of Arthrosamid in Canada, NeuPath has set its sights on expanding its network and providing this promising treatment to more patients, reducing their reliance on temporary painkillers and corticosteroid injections. Through this strategic move, NeuPath aims to address the significant healthcare burden posed by osteoarthritis and provide patients with a more sustainable solution.
